GEN Exclusives

More »

GEN News Highlights

More »
Apr 17, 2012

To-BBB Wins MJFF Funding to Support Preclinical Brain-Targeting Parkinson Disease Drug

  • Dutch brain drug delivery firm to-BBB says it has received funding from The Michael J. Fox Foundation (MJFF) to support preclinical research with 2B3-201, a brain-targeting drug in development for the treatment of neuroinflammation in Parkinson disease (PD). The drug is a brain-targeting, long-acting liposomal formulation of methylprednisolone.

    The firm claims that in contrast to unformulated methylprednisolone, 2B3-201 achieves significantly improved levels of neuroinflammation in preclinical models, and higher brain penetration at lower doses, causing fewer side effects. “Neuroinflammation may play a central role in the progression of Parkinson disease,” explains Audrey Dufour, Ph.D., associate director of research programs at MJFF. “to-BBB has developed an innovative technology to delivery methylprednisolone, an anti-inflammatory drug, into the brain. If results are positive, it could open new avenues for the development and testing of novel therapies for people with PD.”

    To-BBB is exploiting its G-Technology® brain drug delivery platform for the development of treatments against brain-affecting disorders including cancer, neurodegenerative diseases, and lysosomal storage disorders. The platform comprises drug-carrying liposomes coated with glutathione-conjugated PEG, to facilitate safe targeting and enhanced delivery of therapeutic molecules across the blood brain barrier. The firm says the system can transport a range of small molecule and biologic candidates including hydrophilic, lipophilic, and low solubility drugs.

    To-BBB’s lead product, 2B3-101, is a brain-targeting liposomal doxorubicin candidate currently in Phase I/IIa evaluation as a treatment of primary and metastatic brain tumors. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?